IL13 and neoplasm: Fourth, although not statistically significance based on two-way ANOVA tests, tumor-bearing mice that responded to treatment showed an overall increase trend for immune-activating cytokines compared to tumor-bearing mice that failed treatment during weeks 5 through 7 post tumor implantation: GM-CSF (11-fold)76, IL-2 (15-fold)77, IL-13 (8-fold)78, IFN-γ (7-fold)79, and CCL3 (four-fold)80.